

# Funded vaccines for special groups from 1st October 2020

For specific eligibility details, please refer to individual vaccines on the [Pharmaceutical Schedule \(www.pharmac.govt.nz\)](http://www.pharmac.govt.nz).

For vaccine administration schedules, please refer to the online Immunisation Handbook or relevant IMAC fact sheet ([www.immune.org.nz/resources/written-resources](http://www.immune.org.nz/resources/written-resources)).

<p><b>Adolescents and young people 13–25 years inclusively entering specified close-living situations</b></p> <ul style="list-style-type: none"> <li>• Meningococcal vaccine</li> </ul>	<p><b>Immunodeficiency – primary or secondary</b></p> <ul style="list-style-type: none"> <li>• Hib, influenza, meningococcal, and pneumococcal vaccines</li> </ul>
<p><b>Asplenia – Functional or Pre- or Post-Splenectomy Immunisation Programme</b></p> <ul style="list-style-type: none"> <li>• Hib, influenza, meningococcal, pneumococcal, and Tdap vaccines <a href="#">IMAC fact sheet available</a></li> </ul>	<p><b>Influenza Immunisation Programme</b></p> <ul style="list-style-type: none"> <li>» Pregnancy</li> <li>» Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness</li> <li>» Individuals aged 6 months to under 65 years with an eligible medical condition</li> <li>» Individuals aged 65 years or older</li> </ul> <ul style="list-style-type: none"> <li>• Influenza vaccine</li> </ul>
<p><b>Chemotherapy – following</b> <a href="#">IMAC fact sheet available</a></p> <ul style="list-style-type: none"> <li>• Hib, HPV, influenza, pneumococcal, Tdap, and varicella vaccines</li> </ul> <p><b>Also consider immunosuppression for longer than 28 days</b></p> <ul style="list-style-type: none"> <li>• Hepatitis B and meningococcal vaccines</li> </ul>	<p><b>Kidney disease</b> <a href="#">IMAC fact sheet available</a></p> <ul style="list-style-type: none"> <li>• Hepatitis B, Hib, influenza, pneumococcal, Tdap, and varicella vaccines</li> </ul>
<p><b>Cochlear implant</b></p> <ul style="list-style-type: none"> <li>• Hib, influenza, and pneumococcal vaccines</li> </ul>	<p><b>Liver disease</b></p> <ul style="list-style-type: none"> <li>• Hepatitis A and varicella vaccines</li> </ul>
<p><b>Error of metabolism at risk of major metabolic decompensation</b></p> <ul style="list-style-type: none"> <li>• Influenza and varicella vaccines</li> </ul>	<p><b>Meningococcal disease case – contact with</b></p> <ul style="list-style-type: none"> <li>• Meningococcal vaccine</li> </ul>
<p><b>Haematopoietic stem cell transplantation (HSCT) – following</b> <a href="#">IMAC fact sheet available</a></p> <ul style="list-style-type: none"> <li>• Hib, HPV, influenza, meningococcal, pneumococcal, Tdap, and varicella vaccines</li> </ul> <p><b>Also consider immunosuppression for longer than 28 days</b></p> <ul style="list-style-type: none"> <li>• Hepatitis B vaccine</li> </ul>	<p><b>Needle stick injury – following</b></p> <ul style="list-style-type: none"> <li>• Hepatitis B vaccine</li> </ul>
<p><b>Hepatitis A case – contact with</b></p> <ul style="list-style-type: none"> <li>• Hepatitis A vaccine</li> </ul>	<p><b>Non-consensual sexual intercourse – following</b></p> <ul style="list-style-type: none"> <li>• Hepatitis B vaccine</li> </ul>
<p><b>Hepatitis B case – contact with</b></p> <p><b>Infants born to mothers who are hepatitis B surface antigen (HBsAg) positive</b></p> <ul style="list-style-type: none"> <li>• Hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) at birth</li> </ul> <p><b>Household and sexual contacts of known acute hepatitis B cases or carriers</b></p> <ul style="list-style-type: none"> <li>• Hepatitis B vaccine</li> </ul>	<p><b>Neonatal Intensive Care Unit or Specialist Care Baby Unit admission more than 3 days</b></p> <ul style="list-style-type: none"> <li>• Tdap for parents/primary caregivers if maternal Tdap not given at least 14 days before birth</li> </ul>
<p><b>Hepatitis C positive</b></p> <ul style="list-style-type: none"> <li>• Hepatitis B vaccine</li> </ul>	<p><b>Pneumococcal disease – increased risk</b></p> <ul style="list-style-type: none"> <li>• Additional pneumococcal vaccines</li> </ul>
<p><b>HIV positive</b> <a href="#">IMAC fact sheet available</a></p> <ul style="list-style-type: none"> <li>• Hepatitis B, HPV, influenza, meningococcal, pneumococcal, and varicella vaccines</li> </ul>	<p><b>Pregnancy</b> <a href="#">IMAC fact sheet available</a></p> <ul style="list-style-type: none"> <li>• Influenza and Tdap vaccines in every pregnancy</li> </ul>
<p><b>Immunosuppression</b></p> <p><b>Household contacts of children or adults who will be/are immunosuppressed</b></p> <ul style="list-style-type: none"> <li>• Varicella vaccine</li> </ul> <p><b>Prior to elective immunosuppression for longer than 28 days</b> <a href="#">IMAC fact sheet available</a></p> <ul style="list-style-type: none"> <li>• Varicella vaccine</li> </ul> <p><b>Following immunosuppression for longer than 28 days</b> <a href="#">IMAC fact sheet available</a></p> <ul style="list-style-type: none"> <li>• Hepatitis B, Hib, influenza, meningococcal, and Tdap vaccines</li> </ul>	<p><b>Solid organ transplantation</b> <a href="#">IMAC fact sheet available</a></p> <p><b>Prior to solid organ transplantation</b></p> <ul style="list-style-type: none"> <li>• Hepatitis A, hepatitis B, Hib, meningococcal, pneumococcal, Tdap, and varicella vaccines</li> </ul> <p><b>Following solid organ transplantation</b></p> <ul style="list-style-type: none"> <li>• Hepatitis A, hepatitis B, Hib, HPV, influenza, meningococcal, pneumococcal, and Tdap vaccines</li> </ul>
	<p><b>Tuberculosis – infants and children aged under 5 years at risk of tuberculosis (TB) exposure</b></p> <ul style="list-style-type: none"> <li>• BCG vaccine</li> </ul>

Vaccine key – BCG: tuberculosis; Hib: *Haemophilus influenzae* type b; HPV: human papillomavirus; IPV: inactivated polio vaccine; Tdap: tetanus, diphtheria, acellular pertussis.

# Funded vaccines for special groups from 1st October 2020

Vaccine	Individuals eligible for funded vaccine
<i>Haemophilus influenzae</i> type b (Hib) vaccine	<ul style="list-style-type: none"> <li>An additional dose (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; pre- or post-cochlear implant; with functional asplenia; on renal dialysis or a severely immunosuppressive regimen longer than 28 days</li> </ul>
Hepatitis A vaccine	<ul style="list-style-type: none"> <li>One dose for close contacts of a hepatitis A case</li> <li>Two doses for transplant patients; or children with chronic liver disease</li> </ul>
Hepatitis B vaccine or Hepatitis B vaccine and hepatitis B immunoglobulin (HBIG)	<ul style="list-style-type: none"> <li>Infants born to a mother who is hepatitis B surface antigen (HBsAg) positive; children aged under 18 years who are considered not to have achieved a positive serology and require additional vaccination; household or sexual contacts of a known acute hepatitis B case or hepatitis B carrier; individuals who are HIV-positive; hepatitis C positive; solid organ transplant patients (excluding liver or kidney, refer below); following immunosuppression due to steroid or other immunosuppressive therapy; non-consensual sexual intercourse; or needle stick injury (20mcg/mL for infants, children and adults)</li> <li>Adults who are on renal dialysis; or who are liver or kidney transplant patients (40mcg from coadministration of two 20mcg/mL doses)</li> </ul>
Human papillomavirus (HPV) vaccine	<ul style="list-style-type: none"> <li>Three doses for individuals aged 9–26 years inclusively post-solid organ transplantation; post-haematopoietic stem cell transplantation; or who are HIV-positive</li> <li>A maximum of four doses for people aged 9–26 years inclusively post-chemotherapy</li> </ul>
Influenza vaccine	<ul style="list-style-type: none"> <li>Pregnant women in every pregnancy during vaccination season</li> <li>Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness</li> <li>Individuals aged 65 years and older</li> <li>Individuals aged 6 months to under 65 years with certain medical conditions, including individuals pre- or post-splenectomy; or with Down syndrome, cochlear implant, error of metabolism at risk of major metabolic decompensation</li> </ul>
Meningococcal conjugate vaccines	<p><b>Aged under 9 months – MenCCV</b></p> <ul style="list-style-type: none"> <li>Up to three doses (as appropriate) for close contacts of a meningococcal disease case, post-haematopoietic stem cell transplantation; or following immunosuppression due to steroid or other immunosuppressive therapy longer than 28 days</li> </ul> <p><b>Aged 9 months or older – MCV4-D</b></p> <ul style="list-style-type: none"> <li>One dose for close contacts of a meningococcal disease case</li> <li>One dose for individuals aged 13–25 years inclusively who are entering within the next 3 months, or in their first year of living in a boarding school hostel, tertiary education halls of residence, military barrack, or prison</li> <li><b>CATCH UP EXTENDED TO 30 November 2021</b>, one dose for individuals aged 13–25 years inclusively who are in their second, third or more years living in a boarding school hostel, tertiary education halls of residence, military barrack, or prison</li> <li>Two doses for individuals post-haematopoietic stem cell transplantation; or following immunosuppression due to steroid or other immunosuppressive therapy longer than 28 days</li> <li>Up to three doses plus booster doses (as appropriate) for individuals pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; complement deficiency (acquired or inherited); or who are HIV-positive</li> </ul>
Tetanus, diphtheria and pertussis (Tdap) vaccine	<ul style="list-style-type: none"> <li>One dose for pregnant women, in the second or third trimester of every pregnancy</li> <li>One dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days and whose mother did not receive maternal Tdap at least 14 days prior to birth</li> <li>Up to four additional doses (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; on renal dialysis or a severely immunosuppressive regimen</li> </ul>

UPDATED

Continued on next page ...

# Funded vaccines for special groups from 1st October 2020

Vaccine	Individuals eligible for funded vaccine
Pneumococcal conjugate (PCV13) vaccine	<p><b>Infants and children aged under 5 years – up to four age-appropriate doses, and Children aged 12 months to under 18 years who have previously received two doses of PCV10 – up to two doses (as appropriate)</b></p> <ul style="list-style-type: none"> <li>Cardiac disease with cyanosis or failure; cerebrospinal fluid leak; chronic pulmonary disease, including asthma treated with high-dose corticosteroid therapy; cochlear implant; corticosteroid therapy for more than two weeks and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; diabetes; Down syndrome; functional asplenia; post-haematopoietic stem cell transplantation; HIV-positive; immunosuppressive therapy; intracranial shunt; nephrotic syndrome; pre- or post-splenectomy; pre-term infant born before 28 weeks gestation; primary immune deficiency; post-solid organ transplantation; radiation therapy; or renal failure</li> </ul> <p><b>Children aged 5 years or older, and adults – up to four age-appropriate doses</b></p> <ul style="list-style-type: none"> <li>Pre- or post-chemotherapy; post-haematopoietic stem cell transplantation; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; cochlear implant; complement deficiency (acquired or inherited); primary immunodeficiency; on renal dialysis or who are HIV-positive</li> </ul>
Pneumococcal polysaccharide (23PPV) vaccine	<p><b>Children aged 2 years to under 18 years – up to two doses (as appropriate)</b></p> <ul style="list-style-type: none"> <li>Cardiac disease with cyanosis or failure; cerebrospinal fluid leak; chronic pulmonary disease, including asthma treated with high-dose corticosteroid therapy; cochlear implant; corticosteroid therapy for more than two weeks and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; diabetes; Down syndrome; functional asplenia; post-haematopoietic stem cell transplantation; HIV-positive; immunosuppressive therapy; intracranial shunt; nephrotic syndrome; pre- or post-splenectomy; pre-term infant born before 28 weeks gestation; primary immune deficiency; post-solid organ transplantation; radiation therapy; or renal failure</li> </ul> <p><b>Adults aged 18 years or older – up to three doses (as appropriate)</b></p> <ul style="list-style-type: none"> <li>Post-chemotherapy; post-haematopoietic stem cell transplantation; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; cochlear implant; complement deficiency (acquired or inherited); primary immunodeficiency; on renal dialysis or who are HIV-positive</li> </ul>
Tuberculosis BCG vaccine	<p><b>Infants and children aged under 5 years</b></p> <ul style="list-style-type: none"> <li>Living in a house or family with a person with current or past history of tuberculosis (TB), or</li> <li>Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB at 40/100,000 or greater for 6 months or longer, or</li> <li>During their first 5 years will be living 3 months or longer in a country with a rate of TB 40/100,000 or greater</li> </ul>
Varicella vaccine – From age 12 months in primary care – From age 9 months in secondary/hospital care	<p><b>Two doses for non-immune individuals:</b></p> <ul style="list-style-type: none"> <li>Who are HIV-positive with mild or moderate immunosuppression, on the advice of their specialist</li> <li>Prior to elective immunosuppressive therapy that will be longer than 28 days</li> <li>With chronic liver disease who may in future be candidates for transplantation</li> <li>With deteriorating renal function before transplantation</li> <li>Pre-solid organ transplantation</li> <li>Post-chemotherapy; post-haematopoietic stem cell transplantation, on the advice of their specialist</li> <li>Who are immune competent inpatients exposed to varicella, for post-exposure prophylaxis</li> </ul> <p><b>Two doses for individuals with no clinical history of varicella infection or immunisation:</b></p> <ul style="list-style-type: none"> <li>With an inborn error of metabolism at risk of major metabolic decompensation</li> <li>Who are a household contact of a paediatric patient who is immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection or immunisation</li> <li>Who are a household contact of an adult patient who has no clinical history of varicella and who is severely immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection or immunisation</li> </ul>